表紙
市場調查報告書

遊離脂肪酸受體1(G蛋白質共軛型受體40/FFAR1):開發平台分析

Free Fatty Acid Receptor 1 - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 358349
出版日期 內容資訊 英文 69 Pages
訂單完成後即時交付
價格
Back to Top
遊離脂肪酸受體1(G蛋白質共軛型受體40/FFAR1):開發平台分析 Free Fatty Acid Receptor 1 - Pipeline Review, H2 2019
出版日期: 2019年12月27日內容資訊: 英文 69 Pages
簡介

遊離脂肪酸受體1(FFAR1)同時也稱作G蛋白質共軛型受體40,是藉由FFAR1遺傳基因編碼化的A級G蛋白質結合受體。雖然在胰島細胞非常容易發現,但腦內則相當稀少。這個膜蛋白質結合遊離脂肪酸,可調節營養中樞能量平衡。

本報告提供全球各國遊離脂肪酸受體1開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

簡介

  • 調查範圍

概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

研究中的產品的一覽(大學/研究機關別)

治療藥的評估

  • 單劑/併用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Amgen Inc.
  • Advinus Therapeutics Ltd.
  • Astellas Pharma Inc.
  • Caldan Therapeutics Limited
  • Connexios Life Sciences Pvt. Ltd.
  • 第一三共
  • Hyundai Pharmaceutical Co., Ltd.
  • 日本煙草產業
  • Jiangsu Hengrui Medicine Co., Ltd.

藥物簡介

  • AM-1638
  • AM-3189
  • AM-6226
  • AS-2034178
  • AS-2575959
  • CNX-011-67
  • DS-1558
  • HD-6277
  • JTT-851
  • 第二型糖尿病GPR40/GPR120受體激動劑
  • 第二型糖尿病GPR40促效劑
  • 肥胖GPR40拮抗劑
  • 糖尿病GPR40促效劑
  • TUG-770

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC2010TDB

Summary

According to the recently published report 'Free Fatty Acid Receptor 1 - Pipeline Review, H2 2019'; Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) pipeline Target constitutes close to 17 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes.

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Free fatty acid receptor 1 (FFA1), also known as GPR40, is a class A G-protein coupled receptor that is encoded by the FFAR1 gene. It is strongly expressed in the pancreatic islet cells and to a lesser extent in the brain. This membrane protein binds free fatty acids, acting as a nutrient sensor for regulating energy homeostasis.

The report 'Free Fatty Acid Receptor 1 - Pipeline Review, H2 2019' outlays comprehensive information on the Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase I and Preclinical stages are 1, 2 and 10 respectively. Similarly, the universities portfolio in Preclinical stages comprises 4 molecules, respectively. Report covers products from therapy areas Metabolic Disorders, Gastrointestinal, Cardiovascular, Genetic Disorders, Genito Urinary System And Sex Hormones, Infectious Disease, Musculoskeletal Disorders, Oncology and Respiratory which include indications Type 2 Diabetes, Diabetes, Non Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic Steatohepatitis (NASH), Obesity, Acute Lung Injury, Acute Renal Failure (ARF) (Acute Kidney Injury), Chronic Kidney Disease (Chronic Renal Failure), Diabetic Nephropathy, Fibrosis, Hepatitis B, Idiopathic Pulmonary Fibrosis, Liver Cancer, Liver Fibrosis and Myocardial Fibrosis.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1)
  • The report reviews Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Overview
  • Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Companies Involved in Therapeutics Development
  • Amgen Inc
  • Cadila Healthcare Ltd
  • Caldan Therapeutics Ltd
  • Daiichi Sankyo Co Ltd
  • Hyundai Pharmaceutical Co Ltd
  • Johnson & Johnson
  • Liminal BioSciences Inc
  • Merck & Co Inc
  • Scohia Pharma Inc
  • Takeda Pharmaceutical Co Ltd
  • TiumBio Co Ltd
  • Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Drug Profiles
  • AM-3189 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • DS-1558 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • fasiglifam - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • HOB-047 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • MK-2305 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NCE-406 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PBI-4050 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PBI-4547 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SCO-267 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Agonize FFAR1 and PPARG for Type 2 Diabetes - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Agonize GPR40 for Type 2 Diabetes - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Agonize GPR40 for Type 2 Diabetes - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Agonize GPR40 for Type 2 Diabetes Mellitus - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Agonize GPR40 for Type 2 Diabetes - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Agonize PPAR Gamma and GPR40 for Diabetes - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TUG-770 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ZYDG-2 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Dormant Products
  • Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Discontinued Products
  • Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Product Development Milestones
  • Featured News & Press Releases
  • Nov 18, 2019: Liminal presents new preclinical data on PBI-4050 and its effect on Angio-Proliferative Pulmonary Arterial Hypertension
  • Nov 12, 2019: Liminal BioSciences presents new preclinical data on PBI-4050
  • Nov 12, 2019: Liminal BioSciences presents new preclinical data on NASH candidate PBI-4547
  • Nov 11, 2019: Liminal Biosciences presents new preclinical data on PBI-4050 at ASN Kidney Week 2019
  • Oct 25, 2019: Liminal BioSciences announces upcoming presentation on its liver disease drug candidate PBI-4050 at The Liver Meeting 2019
  • Oct 25, 2019: Liminal BioSciences announces presentation on its liver disease drug candidate PBI-4547 at The Liver Meeting 2019
  • Oct 24, 2019: Liminal BioSciences announces upcoming presentation on drug candidate PBI-4050 at ASN kidney week 2019
  • Sep 09, 2019: Prometic reports first subject dosed in phase I clinical study with single ascending doses of PBI-4547
  • Jun 14, 2019: Prometic presents new data on PBI-4050 and its mechanism of action on kidney fibrosis at the 56th ERA/EDTA Congress
  • Jun 11, 2019: Publication regarding a preclinical study of SCO-267, a novel GPR40 agonist
  • Jun 05, 2019: SCOHIA PHARMA to present new preclinical data of SCO267, a GPR40 agonist, at The American Diabetes Association's 79th Scientific Sessions
  • May 22, 2019: Prometic presents new PBI-4050 data on lung fibrosis at the 2019 ATS Conference
  • Dec 05, 2018: Prometic to initiate PBI-4050 pivotal phase 3 clinical trial in Alstrom Syndrome
  • Aug 10, 2018: Prometic announces the publication of PBI-4050's antifibrotic activity in liver diseases in journal of pharmacology and experimental therapeutics
  • Aug 07, 2018: Prometic receives rare pediatric disease designation from U.S. FDA for small molecule drug candidate PBI-4050
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indication, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Number of Products under Investigation by Universities/Institutes, H2 2019
  • Products under Investigation by Universities/Institutes, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by Amgen Inc, H2 2019
  • Pipeline by Cadila Healthcare Ltd, H2 2019
  • Pipeline by Caldan Therapeutics Ltd, H2 2019
  • Pipeline by Daiichi Sankyo Co Ltd, H2 2019
  • Pipeline by Hyundai Pharmaceutical Co Ltd, H2 2019
  • Pipeline by Johnson & Johnson, H2 2019
  • Pipeline by Liminal BioSciences Inc, H2 2019
  • Pipeline by Merck & Co Inc, H2 2019
  • Pipeline by Scohia Pharma Inc, H2 2019
  • Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019
  • Pipeline by TiumBio Co Ltd, H2 2019
  • Dormant Projects, H2 2019
  • Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
Back to Top